ANDA 77424, held by Chartwell RX. Losartan Potassium.
As of Nov 21, 2026, ANDA 77424 (Losartan Potassium), held by Chartwell RX, was first approved by FDA on Oct 6, 2010, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 6, 2010 | Original application | Approved | None posted |
| Losartan Potassium25MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium50MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium100MG · tablet;oral | Losartan Potassium | Rx |
| Jul 13, 2022 | Supplement 15Labeling · Standard review | Approved | None posted |
| Sep 30, 2020 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jun 10, 2016 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 19, 2015 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 19, 2014 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 28, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 21, 2011 | Supplement 3Manufacturing | Approved | None posted |
| Oct 6, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters